Epidemiological data indicate an explosion of type 2 diabetes cases for women after menopause. What is responsible for that? The surprisingly protective role of estrogens, highlighted by the fact that a woman undergoing hormone replacement therapy has up to 35% less risks of developing type 2 diabetes than a woman without treatment.
By elucidating how estrogen affects two of the hormones involved in glucose homeostasis, glucagon and GLP1, researchers prove the value of estrogen supplementation from the onset of menopause. This research, published in JCI Insight, also shows that only one of the three oestrogen receptors seems to be involved in this mechanism. This could ultimately provide much more targeted therapies with a specific molecule that would prevent patients the sometimes embarrassing side effects when treated with a too powerful hormonal therapy.
"A number of scientists are working on the effect of estrogens on pancreatic insulin-producing cells," says and the first author of this work. "But its effect on glucagon-producing cells, another hormone regulating blood sugar, had never been explored before. Indeed, if the pancreas secretes insulin, it also secretes glucagon, a hormone with the opposite effect: insulin captures sugar, while glucagon releases it. Diabetes is therefore due to an imbalance between these two hormones controlling the sugar level in the blood."
Estrogen administration to post-menopausal female mice led the scientists to make a first observation: they identified an increased tolerance to glucose, which is correlated to a lower risk of diabetes. However, if the effect on insulin was expected, the effect on glucagon - and especially on GLP1, an intestinal and pancreatic hormone that increases insulin production - was much less so. These results confirmed the sensitivity to estrogen of pancreatic alpha cells, which then secrete less hyperglycemic glucagon, but more GLP1.
Also released by the intestine during the absorption of meal, this hormone stimulates the secretion of insulin, inhibits the secretion of glucagon and induces the feeling of satiety. The lack of GLP1 is therefore an essential piece - and so far little known - of the onset of diabetes. The role played by GLP1 represents a major explanation of the protection of women regarding diabetes onset before menopause.
"This first observation was already interesting", explains the senior author. "But we went a step further: indeed, the gut harbors cells called the L cells that are very similar to pancreatic alpha cells and whose main function is precisely to produce GLP1. We also observed a strong increase in the production of GLP1 in the gut cells, thus proving the crucial role of the intestine in the control of carbohydrate balance and the influence of estrogens on the entire metabolisms at stake". These results were also confirmed on human cells and tissue samples.
Hormonal substitution treatments are often subject to negative publicity, mainly because of the cardiovascular risks associated with them. “It is important to remember that hormonal substitution, when taken at the beginning of menopause and for a few years only, does not cause any particular risk of cardiovascular events”, stresses Jacques he author. "However, if hormonal treatment is taken more than 10 years after menopause, the cardiovascular risk is effectively increased. In the context of diabetes, an estrogenic treatment allows to avoid, in all cases, the explosion of female diabetes cases. These treatments, well administered, can really add value for women's health."
In their study, the researchers were also able to dissect the fine cellular mechanisms involved: Of the three estrogens receptors, only one is mainly involved in this protective effect. It would therefore be possible to develop a molecule that only activates the interesting receptor, with a much more targeted effect. "One could imagine a treatment that, without the side effects of a little too powerful hormonal therapy, would also address men", concludes the senior author.
https://www.unige.ch/communication/communiques/en/2018/diabete-le-role-protecteur-des-strogenes-enfin-compris/
https://insight.jci.org/articles/view/98569
Latest News
Abusive drugs hijack natura…
By newseditor
Posted 23 Apr
Mechanism of action of the…
By newseditor
Posted 23 Apr
Role of fat in rare neurolo…
By newseditor
Posted 23 Apr
How protein synthesis in de…
By newseditor
Posted 22 Apr
Atlas of mRNA variants in d…
By newseditor
Posted 22 Apr
Other Top Stories
Novel chip-based gene expression tool analyzes RNA quickly and accu…
Read more
Vitamin C in the body can be tracked by fluorescence
Read more
'Smart' contact lenses monitor glucose levels in tears
Read more
Anxiety Cells' Identified in the Brain's Hippocampus
Read more
Cryo-EM structure of full length serotonin receptor
Read more
Protocols
A programmable targeted pro…
By newseditor
Posted 23 Apr
MemPrep, a new technology f…
By newseditor
Posted 08 Apr
A tangible method to assess…
By newseditor
Posted 08 Apr
Stem cell-derived vessels-o…
By newseditor
Posted 06 Apr
Single-cell biclustering fo…
By newseditor
Posted 01 Apr
Publications
Exploiting pancreatic cance…
By newseditor
Posted 23 Apr
Structure of antiviral drug…
By newseditor
Posted 23 Apr
Type-I-interferon-responsiv…
By newseditor
Posted 23 Apr
Selenium, diabetes, and the…
By newseditor
Posted 23 Apr
Long-term neuropsychologica…
By newseditor
Posted 23 Apr
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar